Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.70 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10455034 | 0.87 | PSIP1 (0.74) | PLCG1PSIP1GAACA2KMT2A | |
| SCHEMBL198253 | 0.84 | PLCG1 (0.61) | PLCG1GAACA2KMT2ACYP1A2 | |
| SCHEMBL3253487 | 0.82 | PLCG1 (1.00) | PLCG1CA2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL5104880 | 0.81 | PLCG1 (0.57) | PLCG1CA2KMT2ACYP3A4CYP2C9 | |
| SCHEMBL9704914 | 0.80 | PLCG1 (0.70) | PLCG1CA2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL10266897 | 0.79 | PLCG1 (0.55) | PLCG1PSIP1GAACA2KMT2A | |
| SCHEMBL14543475 | 0.79 | PLCG1 (0.55) | PLCG1CA2KMT2ACYP3A4CYP2C9 | |
| SCHEMBL3109600 | 0.78 | PLCG1 (0.67) | PLCG1CA2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL165340 | 0.78 | PLCG1 (0.67) | PLCG1CA2KMT2ACYP1A2CYP3A4 | |
| SCHEMBL8488156 | 0.78 | PLCG1 (0.67) | PLCG1PSIP1GAACA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 563 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240425504-A1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (assignee) (JP) | 2024-12-26 | — | — | US | disclosed |
| EP-3808747-B1 | IMIDAZOPYRIDINONE COMPOUND | KISSEI PHARMACEUTICAL (JP) | 2024-12-18 | — | — | EP | disclosed |
| US-12077531-B2 | Imidazopyridinone compound | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2024-09-03 | — | — | US | disclosed |
| CN-113302185-B | Benzofuran-6-carboxamide derivatives, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-30 | — | — | US | disclosed |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-14 | — | — | US | disclosed |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-14 | — | — | US | disclosed |
| CN-112689637-B | Imidazopyridone compounds | 橘生药品工业株式会社 | 2023-11-10 | — | — | CN | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| CN-1042539-C | 11,21-bisphenyl-19-norpregnane derivatives | AKZO NOBEL NV (NL) | 1999-03-17 | — | — | CN | disclosed |
| EP-0683172-B1 | 11,21-Bisphenyl-19-norpregnane derivatives | AKZO NOBEL NV (NL) | 1997-08-13 | — | — | EP | disclosed |
| US-5620966-A | ANTIGLUOCORTICOID ACTIVITY | AKZO NOBEL N.V. (NL) | 1997-04-15 | — | — | US | disclosed |
| CN-1126727-A | 11,21-bisphenyl-19-norpregnane derivatives | AKZO NOBEL NV (NL) | 1996-07-17 | — | — | CN | disclosed |
| EP-0683172-A1 | 11,21-Bisphenyl-19-norpregnane derivatives | Akzo Nobel N.V. (NL) | 1995-11-22 | — | — | EP | disclosed |
| EP-0412387-B1 | Diarylacetylenes, their process and use | BASF AG (DE) | 1993-11-24 | — | — | EP | disclosed |
| US-5087637-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1992-02-11 | — | — | US | disclosed |
| EP-0412387-A2 | Diarylacetylenes, their process and use | BASF Aktiengesellschaft (DE) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | PLCG1 1595/4885PSIP1 333/4885GAA 3422/4885 |
| US-12077531-B2 | Imidazopyridinone compound | EGLN3, DHPS, EGLN2 | PLCG1 3942/4885PSIP1 623/4885GAA 1889/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | PLCG1 1871/4885PSIP1 3791/4885GAA 1379/4885 |
| US-20240425504-A1 | IMIDAZOPYRIDINONE COMPOUND | EGLN3, DHPS, EGLN2 | PLCG1 3942/4885PSIP1 623/4885GAA 1889/4885 |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | PLCG1 758/4885PSIP1 430/4885GAA 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.